The Revitalized Tau Hypothesis on Alzheimer's Disease

Archives of Medical Research

Volumn 41, Issue 3, 2010, Pages 226-231

  Maccioni, Ricardo B ^a   Farías, Gonzalo ^a   Morales, Inelia ^a   Navarrete, Leonardo ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Activation of microglia; Alzheimer's disease; Damage signals; Neuronal cells; Proinflammatory factors; Tau oligomers.; Tau phosphorylations

Indexed keywords

AMYLOID BETA PROTEIN; ANTHRAQUINONE DERIVATIVE; CHOLESTEROL; CYANINE DYE; HEAT SHOCK PROTEIN 90; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; METHYLENE BLUE; MITOGEN ACTIVATED PROTEIN KINASE; NEUROFILAMENT PROTEIN; PLACEBO; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; DISEASE COURSE; HUMAN; IMMUNOMODULATION; IRON OVERLOAD; MICROGLIA; NERVE CELL DEGENERATION; NONHUMAN; OLIGOMERIZATION; PATHOPHYSIOLOGY; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; ANIMALS; HUMANS; MICE; MODELS, NEUROLOGICAL; NEUROIMMUNOMODULATION; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 77953499350     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2010.03.007     Document Type: Article

References (49)

1. Alzheimer A. A singular disorder that affects the cerebral cortex. Neurologic Classics in Modern Translation 1977, 41-43. Hafner Press, New York. C.N. Hochberg, F.H. Hochberg (Eds.).
2. Maccioni R.B., Concha I., Otths C., et al. The protein kinase cdk5: structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology. Eur J Biochem 2001, 268:1518-1529.
3. Maccioni R.B., Barbeito L., Muñoz J.P. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch Med Res 2001, 32:367-381.
4. Kosik K.S., Joachim C.L., Selkoe D.J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA 1986, 83:4044-4048.
5. Grundke-Iqbal I., Iqbal K., Tung Y.C., et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986, 83:4913-4917.
6. Maccioni R.B., Cambiazo V. Role of microtubule-associated proteins in the control of microtubule assembly. Physiol Rev 1995, 75:835-864.
7. Rojo L., Fernandez J., Maccioni A.A., et al. Neuro-inflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 2008, 39:1-16.
8. Fernandez J., Rojo L.E., Kuljis R.O., et al. The damage signal hypothesis of AD. J Alzheimers Dis 2008, 14:329-333.
9. Maccioni R.B., Rojo L.E., Fernandez J.A., et al. The role of neuroimmunomodulation in Alzheimer's disease. Ann NY Acad Sci 2009, 1153:240-246.
10. Maccioni R.B., Vera J.C., Dominguez J., et al. A discrete repeated sequence defines a tubulin binding domain on microtubule-associated protein tau. Arch Biochem Biophys 1989, 275:568-579.
11. González-Billault C., Farías G., Maccioni R.B. Modification of tau to an Alzheimer's type protein interferes with its interaction with microtubules. Cell Mol Biol 1998, 44:1117-1127.
12. Farias G., Gonzalez C., Maccioni R.B. Immunological characterization of epitopes on tau of Alzheimer's type and chemically modified tau. Mol Cell Biochem 1997, 168:59-66.
13. Ghoshal N., García-Sierra F., Wuu J., et al. Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease. Exp Neurol 2002, 177:475-493.
14. Maccioni R.B., Lavados M., Maccioni C.B., et al. Anomalously phosphorylated tau protein and Abeta fragments in the CSF of Alzheimer's and MCI subjects. Neurobiol Aging 2006, 27:237-244.
15. Duff K., Kuret J., Congdon E.E. Disaggregation of Tau as a therapeutic approach to Tauopathies. Curr Alzheimer Res 2010 Jan 21, [Epub ahead of print].
16. Tabaton M., Mandybur T.I., Perry G., et al. The widespread alteration of neurites in Alzheimer's disease may be unrelated to amyloid deposition. Ann Neurol 1989, 26:771-778.
17. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
18. Ferreira S.T., Vieira M.N., De Felice F.G. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. Life 2007, 59:332-345.
19. Maccioni R.B., Lavados M., Maccioni C.B., et al. Biological markers of Alzheimer's disease and mild cognitive impairment. Curr Alzheimers Res 2004, 1:307-314.
20. Morales I., Farias G., Maccioni R.B. Neuroimmunomodulation in the pathogenesis of Alzheimer's disease. Neuroimmunomodulation 2010, 17:202-204.
21. Delacourte A. The natural and molecular history of Alzheimer's disease. J Alzheimers Dis 2006, 9:187-194.
22. Berger Z., Roder H., Hanna A., et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 2007, 27:3650-3662.
23. Maeda S., Sahara N., Saito Y., et al. Granular tau oligomers as intermediates of tau filaments. Biochemistry 2007, 46:3856-3861.
24. Maeda S., Sahara N., Saito Y., et al. Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Neurosci Res 2006, 54:197-201.
25. Perez M., Arrasate M., Montejo de Garcini E., et al. In vitro assembly of tau protein: mapping the regions involved in filament formation. Biochemistry 2001, 40:5983-5991.
26. Sibille N., Sillen A., Leroy A., et al. Structural impact of heparin binding to full-length tau as studied by NMR spectroscopy. Biochemistry 2006, 45:12560-12572.
27. von Bergen M., Berghorns S., Biernat J., et al. Tau aggregation is driven from a transition coil to beta sheet structure. Biochem Biophys Acta 2005, 3:1739.
28. Mukrasch M.D., Markwick P., Biernat J., et al. Highly turn conformations in natively unfolded tau protein identified from residual dipolar couplings and molecular simulation. J Am Chem Soc 2007, 129:5235-5243.
29. Avila J., Perez M., Lucas J., et al. Assembly in vitro of tau protein and its implications in Alzheimer's disease. Curr Alzheimers Res 2004, 1:97-101.
30. Maccioni R.B. Potential clues toward Alzheimer's disease treatment. Rev Farmacol Chile 2009, 2:34.
31. Jeganathan S., von Bergen M., Mandelkow E.M., et al. The natively unfolded character of tau and its aggregation to Alzheimer-like paired helical filaments. Biochemistry 2008, 47:10526-10539.
32. Alvarez A., Muñoz J.P., Maccioni R.B. A cdk5/p35 stable complex is involved in the beta-amyloid induced deregulation of cdk5 activity in hippocampal neurons. Exp Cell Res 2001, 264:266-275.
33. Otth C., Concha, Arendt T., et al. A betaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J Alzheimers Dis 2002, 4:417-430.
34. Zambrano C.A., Egana J.T., Nunez M.T., et al. Oxidative stress promotes tau dephosphorylation in neuronal cells: the roles of cdk5 and PP1. Free Radic Biol Med 2004, 36:1393-1402.
35. Lavados M., Guillon M., Mujica M.C., et al. Mild cognitive impairment and Alzheimer's patients display different levels of redox-active CSF iron. J Alzheimers Dis 2008, 13:225-232.
36. Neumann K., Navarrete L., Rojo L., et al. Insulin resistance and Alzheimer's disease: molecular links and clinical implications. Curr Alzheimers Res 2008, 5:438-447.
37. Orellana D.I., Quintanilla R.A., Maccioni R.B. Neuroprotective effect of TNFalpha against the beta-amyloid neurotoxicity mediated by cdk5 kinase. Biochim Biophys Acta 2007, 1773:254-263.
38. Schwab C., McGeer P.L. Inflammatory aspects of Alzheimer's disease and other neurodegenerative disorders. J Alzheimers Dis 2008, 13:359-369.
39. Quintanilla R.A., Orellana D.I., Gonzalez-Billault C., et al. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res 2004, 295:245-257.
40. Saez E.T., Pehar M., Vargas M., et al. Production of NGF by β amyloid stimulated astrocytes induces p75NTR-dependent tau hyperphosphorylation in cultured hypocampal cells. J Neurosci Res 2006, 84:1098-1106.
41. Saez E.T., Pehar M., Barbeito L., et al. Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons. In vivo 2004, 18:275-280.
42. Leclerc E., Sturchler E., Vetter S.W., et al. Crosstalk between calcium, amyloid beta and the receptor for advanced glycation endproducts in Alzheimer's disease. Rev Neurosci 2009, 20:95-110.
43. Jinwal U.K., Koren J., Borysov S.I., et al. Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules. J Neurosci 2010, 13(30):591-599.
44. Luo W., Dou F., Rodina A., et al. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci USA 2007, 104:9511-9516.
45. Noble W., Planel E., Zehr C., et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 2005, 102:6990-6995.
46. Le Corre S., Klafki H.W., Plesnila N., et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci USA 2006, 103:9673-9678.
47. Oz M., Lorke D., Petroianu G. Methylene blue and Alzheimer's disease. Biochem Pharmacol 2009, 78:927-932.
48. Pickhardt M., Gazova Z., Bergen M., et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J Biol Chem 2005, 280:3628-3635.
49. Rojo L.E., Alzate-Morales J., Saavedra I.N., et al. Selective interaction of lansoprazole and astemizole with Tau polymers: potential new clinical use in diagnosis of Alzheimer's disease. J Alzheimers Dis 2010, 19:573-589.